Gene Therapy Clinical Trial Services Market Report 2026

The gene therapy clinical trial services market size has grown rapidly in recent years. It will grow from $1.82 billion in 2025 to $2.18 billion in 2026 at a compound annual growth rate (CAGR) of 19.4%. The growth in the historic period can be attributed to increasing investment in gene therapy R&D, expansion of early-stage gene therapy pipelines, rising collaboration between biotech firms and CROs, growing complexity of gene therapy trial protocols, increased regulatory scrutiny of advanced therapies.

The gene therapy clinical trial services market size is expected to see rapid growth in the next few years. It will grow to $4.39 billion in 2030 at a compound annual growth rate (CAGR) of 19.1%. The growth in the forecast period can be attributed to increasing number of late-stage gene therapy trials, rising demand for global trial execution capabilities, expansion of rare disease gene therapy programs, growing use of digital trial management platforms, increasing focus on accelerated regulatory approvals. Major trends in the forecast period include increasing demand for specialized gene therapy trial management, rising adoption of decentralized and hybrid trial models, growing focus on advanced cold chain and logistics support, expansion of patient-centric trial design approaches, enhanced emphasis on regulatory and data integrity services.

The growing demand for personalized medicine is expected to drive the expansion of the gene therapy clinical trial services market in the coming years. Personalized medicine tailors medical treatment to individual characteristics, including genetic profiles, biomarkers, and lifestyle factors. This demand is increasing due to advancements in genomics and biotechnology, which allow therapies to be more precisely targeted. Gene therapy clinical trial services support personalized medicine by analyzing patient-specific genetic information and customizing treatments accordingly, using biomarker analysis and companion diagnostics to optimize therapy for each patient while enhancing safety and efficacy. For example, in February 2024, the Personalized Medicine Coalition, a US-based healthcare organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022. Therefore, the rising demand for personalized medicine is fueling the growth of the gene therapy clinical trial services market.

Leading companies in the gene therapy clinical trial services market are developing innovative solutions, such as long-term follow-up (LTFU) models for cell and gene therapy (CGT) trials, to accelerate trial processes while maintaining regulatory compliance and safety standards. LTFU models provide a structured framework for monitoring patients over extended periods, often up to 15 years after receiving CGT treatments. For instance, in May 2025, Medable Inc., a US-based SaaS company, launched a digital-first LTFU model specifically for CGT trials. This platform reduces burdens on patients and trial sites while ensuring scientific rigor throughout the FDA-required 15-year monitoring period. It enhances patient access, retention, and data continuity through remote and hybrid follow-up methods, improving long-term safety and efficacy monitoring.

In January 2024, Kyowa Kirin Co., Ltd., a Japan-based pharmaceutical company, acquired Orchard Therapeutics plc for an undisclosed amount. This acquisition strengthens Kyowa Kirin’s gene therapy capabilities and expands its presence in the advanced therapies sector, particularly in rare diseases and genetic disorders. Orchard Therapeutics plc, based in the UK, specializes in providing gene therapy clinical trial services.

Major companies operating in the gene therapy clinical trial services market are Thermo Fisher Scientific Inc., Sharp Services LLC, Labcorp, Pharmaceutical Product Development LLC, ICON plc, Syneos Health Inc., WuXi AppTec, Franklin Biolabs, Catalent Inc., Charles River Laboratories International Inc., Parexel International Corporation, Medpace Holdings Inc., Precision Medicine Group LLC, Worldwide Clinical Trials, IQVIA Holdings Inc., TFS HealthScience, Veristat LLC, Novotech Health Holdings Pte Limited, Covance Inc., PPD Clinical Research Services, PRA Health Sciences Inc.

North America was the largest region in the gene therapy clinical trial services market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy clinical trial services market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gene therapy clinical trial services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the gene therapy clinical trial services market by increasing costs associated with imported laboratory equipment, cold chain storage systems, specialized reagents, and clinical trial supplies used in advanced gene therapy studies. North America and Europe are most affected due to reliance on cross-border shipment of trial materials, while Asia-Pacific faces higher logistics and compliance costs for multinational trials. These tariffs are elevating operational expenses and extending trial timelines. However, they are also encouraging regional trial infrastructure development, local sourcing of clinical supplies, and greater investment in domestic clinical research capabilities.

The gene therapy clinical trial services market research report is one of a series of new reports that provides gene therapy clinical trial services market statistics, including gene therapy clinical trial services industry global market size, regional shares, competitors with a gene therapy clinical trial services market share, detailed gene therapy clinical trial services market segments, market trends and opportunities, and any further data you may need to thrive in the gene therapy clinical trial services industry. This gene therapy clinical trial services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gene therapy clinical trial services encompass the specialized support, infrastructure, and expertise required to design, manage, and execute clinical trials evaluating gene therapy products in humans. These services cover a wide range of activities to ensure investigational gene therapies are tested safely, ethically, and efficiently, while generating robust clinical evidence to support regulatory approval and potential commercialization.

The primary types of gene therapy clinical trial services include clinical trial design and planning, supply and logistics services, regulatory support, data management and biostatistics, site management and monitoring, and others. Clinical trial design and planning involves outlining a study’s objectives, methodologies, timelines, and analysis to ensure scientific validity and regulatory compliance. These services are applied across multiple therapeutic areas, including oncology, hematology, endocrine and metabolic disorders, musculoskeletal diseases, cardiovascular diseases, neurological disorders, infectious diseases, ophthalmology, immunology, and more. They serve a variety of end users, such as pharmaceutical and biotechnology companies, academic institutions, government research organizations, and contract research organizations.

The gene therapy clinical trial services market includes revenues earned by entities by providing services such as patient recruitment and enrollment, clinical trial site selection and setup, pharmacovigilance and safety monitoring, biomarker analysis and companion diagnostics, and training and support for clinical staff. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.